GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Accounts Receivable

Paratek Pharmaceuticals (FRA:N4CN) Accounts Receivable : €39.0 Mil (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Paratek Pharmaceuticals's accounts receivables for the quarter that ended in Jun. 2023 was €39.0 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Paratek Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2023 was 101.39.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Paratek Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was €-4.30.


Paratek Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Paratek Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Accounts Receivable Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 7.63 9.76 26.05 70.48

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.98 29.70 70.48 34.46 39.04

Paratek Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Paratek Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Paratek Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=39.035/35.131*91
=101.39

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Paratek Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Paratek Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(39.398+0.75 * 39.035+0.5 * 10.534-320.426
-0-0)/57.2822
=-4.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Paratek Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines